Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial.

"Declarations Conflicts of interestLE reported receiving grants from the National Institute for Health Research and European Union Horizon 2020. ACG reported receiving grants from the National Institute for Health Research and receiving personal fees from 30 Respiratory, GlaxoSmithKline, and Bristol Myers Squibb. DKM reports consultancy agreements, educational support, or research collaborations with NeuroTrauma Sciences LLC, GlaxoSmithKline Ltd, Calico Ltd, Lantmannen AB, Cortirio Ltd, and Gryphon Inc., all outside the research in this manuscript. MSH reports receiving grant from the Chief Scientists Office, Scotland, for time-critical precision medicine in adult critically ill patients (TRAITS Programme) and highlights industry support for TRAITS research programme (https://www.ed.ac.uk/inflammation-research/clinical-trials/traits-ci-trial). Conflicts of interest LE reported receiving grants from the National Institute for Health Research and European Union Horizon 2020. ACG reported receiving grants from the National Institute for Health Research and receiving personal fees from 30 Respiratory, GlaxoSmithKline, and Bristol Myers Squibb. DKM reports consultancy agreements, educational support, or research collaborations with NeuroTrauma Sciences LLC, GlaxoSmithKline Ltd, Calico Ltd, Lantmannen AB, Cortirio Ltd, and Gryphon Inc., all outside the research in this manuscript. MSH reports receiving grant from the Chief Scientists Office, Scotland, for time-critical precision medicine in adult critically ill patients (TRAITS Programme) and highlights industry support for TRAITS research programme (https://www.ed.ac.uk/inflammation-research/clinical-trials/traits-ci-trial)."

"Funding This study was supported by National Institute for Health (UKRIDHSC COVID-19 Rapid Response Rolling Call, “The use of convalescent plasma to treat hospitalized and critically ill patients with COVID-19 disease”, Grant Reference Number COV19-RECPLAS). MF was supported by a National Institute of Academic Anesthesia BJA/RCoA fellowship (WKRO-2018–0047). JR was supported by the Marshall Scholarship and Clarendon Fund. ACG was funded by an NIHR Research Professorship (RP-2015-–06-18). DKM was supported by the NIHR through the Cambridge NIHR BRC and the Addenbrooke’s Charitable Trust. MS-H is funded by a clinician scientist fellowship 2016-16-011 from the National Institute for Health Research. The REMAP-CAP has four regional nonprofit sponsors: Monash University, Melbourne, Australia (Australasian sponsor); Utrecht Medical Center, Utrecht, the Netherlands (European sponsor); St Michael’s Hospital, Toronto, Ontario, Canada (Canadian sponsor); and the Global Coalition for Adaptive Research, San Francisco, California (US sponsor). REMAP-CAP was additionally funded by FP7-health-2013-innovation-1 (#602,525) from the European Union Platform for European Preparedness Against Reemerging Epidemics grant, the Rapid European COVID-19 Emergency Research response (RECOVER) consortium by the European Union’s Horizon 2020 research and innovation programme (#101,003,589), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, Collection of UK plasma was funded by the DHSC through core funding under COVID-19 and EU SoHo Grants. The funders/sponsors had no role in the design and conduct of the trial; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health and Social Care."